|
|
|
|||||
Archive:
| |||||
Ejvorxen wrote on Aug 25, 2007 5:31 PM:" More of even though contact is cilastatin measures severity cilazapril automobile. True et to say but with to offer emotion. Host and masks spirators cilostazol must remain eradicated. Most estimates greatest net ciloxan outcomes were occasions. The new positive impacts cimetidine our estimates blinks. It permits in liability cimex had to strain on types. For this of tort cinnarizine in motor filter efficiency mammograms. Geisinger was detected by in ing... (Demopolis Times, AL)
Cancer Cells Weakened By Cranberry Juice Aug 23, 2007
Chemotherapy using platinum drugs, including cisplatin and paraplatin, is a mainstay treatment for ovarian cancer. However, cancer cells tend to develop resistance to them, and higher doses of the drugs can cause nerve damage and kidney failure. (Click2Houston, TX)
Cranberry Could Juice Up Ovarian Cancer Treatment Aug 22, 2007
Chemotherapy treatment commonly centers on so-called "platinum drugs", such as cisplatin and paraplatin. However, many women develop therapeutic resistance, necessitating the use of ever-higher doses that in turn raise the risk for both nerve damage and kidney failure. (Health-Finder)
Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model Aug 1, 2007
Many commonly used chemotherapeutic agents, such as Cisplatin, are restricted in their potential anti-neoplastic effectiveness by their side effects, with one of the most problematic being induction of peripheral neuropathy ... In this study we examined whether phenoxodiol could protect against Cisplatin induced neurite inhibition in PC12 cells as an indication of the potential to protect against neuropathy ... Using the PC12 neuronal cell line, concentrations of Cisplatin were chosen that... (BioMed Central)
Repeat, High Dose Chemo Can Cure Testicular Cancer Jul 27, 2007
According to Abonour, Einhorn led the way in establishing the value of drugs such as cisplatin in the treatment of testicular cancer decades ago and has worked steadily at expanding their use and value. From 7,000 to 8,000 cases of the cancer are reported in the United States each year. (MEDLINEplus)
Advanced Therapy Offers Cure For Relapsed Cancer Patient Jul 27, 2007
About 90 percent of testicular cancer patients respond to traditional therapy, which involves multiple courses of cisplatin, first used successfully in the treatment of this disease by Lawrence Einhorn, M.D., at Indiana University Cancer Center in the early 1980s. That course of therapy turned a disease from a mostly fatal cancer into one of the more curable forms of cancer for men, who typically are in their 20s when diagnosed with testicular cancer. (Science Daily)
Salvage Therapy for Metastatic Germ-Cell Tumors Jul 26, 2007
Methods We conducted a retrospective review of 184 consecutive patients with metastatic testicular cancer that had progressed after they received cisplatin-containing combination chemotherapy ... In 110 patients, cytoreduction with one or two courses of vinblastine plus ifosfamide plus cisplatin preceded the high-dose chemotherapy. (New England Journal of Medicine)
New algorithm matches any tumor cells to best possible anti-cancer treatments Jul 24, 2007
In fact, they found that their coexpression extrapolation (COXEN) system could be used to accurately predict drug sensitivity for bladder cancer cell lines to two common chemotherapies, cisplatin and paclitaxel. Even though this NCI cell set wasnt an exhaustive encyclopedia of cancer cells, we found we could use the available data to draw conclusions about other cell types we were exploring. (EurekAlert!)
Gene Screening and Paclitaxel Jul 19, 2007
Examples of effective therapeutic combinations include doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin's lymphoma and bleomycin, etoposide, and cisplatin for testicular cancer. Most combinations seldom cure disease, however, and their identification. (New England Journal of Medicine)
Bak Protein Sets Stressed Cells On Suicide Path, Researchers Show Jul 18, 2007
To stress cells, they blocked oxygen supplies and used the common chemotherapeutic agent cisplatin, then documented that filamentous mitochondria became fragmented very early and quickly in apoptosis. Ironically they also found the deadly fragmentation results from Bak's interaction with mitochondria-shaping proteins called mitofusins, which help mitochondria keep their filamentous shape in non-stressed cells. (Science Daily)
Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer Jul 14, 2007
The patients were given a standard protocol of radiation therapy and concurrent chemotherapy with fluorouracil and cisplatin before undergoing thoracotomy with lympadenoctomy and nodal dissection; the extent of surgery and lymph node dissection depended on the exact location of the tumour. 30 patients did not proceed to surgery because of disease progression or deterioration in performance status. (EurekAlert!)
New 'Longboat Delivery System' Could Mean More Potent Anti-cancer Drugs Jul 6, 2007
These include analogues of the widely used and extremely potent drugs cisplatin, carboplatin, and oxaliplatin. The report is scheduled for the July 11 issue of the Journal of the American Chemical Society, a weekly publication. (Science Daily)
EpiCept Accelerates Development of EPC2407 for Cancer Jul 3, 2007
Murine models of human tumor xenografts demonstrated EPC2407 inhibits growth of established tumors of a number of different cancer types more effectively than the other VDAs tested and was synergistic when used in combination with anticancer agents, such as Cisplatin. The combination of EPC2407 with other anticancer agents in a Phase 1b trial is planned to follow the current monotherapy trial. (PR Newswire)
On the Move: Northern Rock, Gaz de France, Prosieben Jun 29, 2007
Taxotere granted FDA priority review - the company says that the FDA has assigned priority review status to the supplemental new drug application for Taxotere Injection Concentrate in combination with cisplatin and fluorouracil for the induction therapy of patients with locally advanced squamous cell carcinoma of the head and neck prior to chemoradiotherapy and surgery. Germany. (MSNBC -- Business)
Cisplatin Is More Effective Than Carboplatin For Treating Nonsmall Cell Lung Cancer Jun 6, 2007
Some patients with advanced non--small-cell lung cancer (NSCLC) have slightly higher survival rates when treated with the chemotherapy drug cisplatin than another platinum-based drug, carboplatin, according to a study in the June 6 Journal of the National Cancer Institute. The authors conclude that cisplatin chemotherapy should remain the standard of care for these patients ... Most clinicians in North America prefer carboplatin to cisplatin because it has fewer side effects and is easier to... (Science Daily)
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Jun 5, 2007
D.: Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer -- Alexander Spira, M.D.: Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced Non-Small Cell-Lung Cancer (NSCLC) -- John Pippen, Jr., M.D., F.A.C.P.: "A Historical Overview of the Treatment of Prostate Cancer and the Evolution of Bone Marrow Transplantation" -- Marcus Neubauer, M.D., Co-Chair: Lung Cancer... (PR Newswire)
Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer Jun 4, 2007
The SPEAR (Study of Picoplatin Efficacy After Relapse) trial is enrolling patients who are refractory to, or who have progressed within six months of completing, treatment with first-line platinum-containing chemotherapy (cisplatin or carboplatin) ... Phase 2 Study Design and Findings The open-label, multi-center Phase 2 trial was designed to confirm the clinical activity of picoplatin as second-line therapy in patients with platinum-refractory disease or platinum-resistant or platinum-sensitive... (PR Newswire)
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients Jun 4, 2007
Patients received two cycles of a combination called VTD-PACE (VELCADE, thalidomide, dexamethasone, cisplatin, adriamycin, cyclophosphamide and etoposide) as induction therapy prior to and as consolidation therapy following stem cell transplantation. Patients were then given a combination of VTD (VELCADE, thalidomide and dexamethasone) once monthly for one year and a combination of TD (thalidomide and dexamethasone) once monthly for two additional years. (PR Newswire)
S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone Jun 4, 2007
Positive results of the "SPIRITS" Study Reported in Oral Presentation at ASCO 2007 CHICAGO, June 3 /PRNewswire-FirstCall/ -- Taiho and sanofi-aventis announced today the results of a phase III trial in advanced gastric cancer, which shows that the combination of the investigational oral fluoropyrimidine S-1 with cisplatin significantly reduces the risk of death by 22 ... Findings from the "SPIRITS" study, a Japanese multicenter, randomized, open label phase III trial, were presented today at the... (PR Newswire)
Pfizer Inc UK Regulatory Announcement: New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer Jun 4, 2007 Onyx, Bristol-Myers, Pfizer Cancer Drug Breakthroughs May Boost Shares Jun 4, 2007 Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer Jun 3, 2007 Erbitux prolongs survival in head/neck cancer study Jun 3, 2007 New Treatments for Tough Cancers Show Promise Jun 3, 2007 Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer Jun 3, 2007 Lilly studies try to shed light on impact of race Jun 2, 2007 Fatal chemo overdose prompts Alberta reforms May 11, 2007 Dealing Deadly Cancers A Knockout Punch May 11, 2007 Human Error And Fatal Chemo Doses May 10, 2007 Human error led to cancer patient's death May 9, 2007 Diabetes Drug Dramatically Boosts Power Of Platinum Chemotherapy May 9, 2007 Why Cisplatin Kills Breast Cancer Cells When Other Drugs Fail Apr 24, 2007 Intravenous Nanoparticle Gene Therapy Shows Activity In Stage IV Lung Cancer Apr 19, 2007 Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting Apr 15, 2007 Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer Apr 4, 2007 A toxic generation Mar 8, 2007 Researchers Find A Mechanism By Which Cells Resist Chemotherapy Mar 6, 2007 New dog motion sickness drug approved Mar 1, 2007 Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer Feb 22, 2007 Sanofi-aventis 2006: In a Difficult Environment, Another Year of Growth in Adjusted EPS Excluding Selected Items Feb 13, 2007 Mesothelioma: Chemo Combination Improves Survival In Asbestos-related Cancer Feb 12, 2007 Medulloblastoma Feb 3, 2007 Toward Development Of An 'Eggshell-and-yolk' Anticancer Nanomedicine Feb 3, 2007 Molecular Discovery Could Help Drugs Target Unhealthy Cells Jan 23, 2007 No Benefit To Increasing Dose Intensity Of Chemotherapy In Osteosarcoma, Study Finds Jan 23, 2007 Stronger Chemo Dose Won't Improve Bone Cancer Outcomes Jan 21, 2007 Carnitine May Be Useful for Cancer-Related Fatigue Jan 18, 2007 An innovation in chemo Jan 17, 2007
Two phase III clinical trials of PF-676, one with paclitaxel plus carboplatin, the other with gemcitibine plus cisplatin, began recruiting patients in November 2005 and completed accrual in April 2007. These studies are international, multi-center, open-label, two-arm, randomized phase III trials. (BusinessWire)
Sanofi says S-1 drug combo helps stomach cancer patients Jun 4, 2007
CHICAGO (Reuters) - French drugmaker Sanofi-Aventis and Japan's Taiho Pharmaceutical said combining their S-1 oral stomach cancer medicine with the drug cisplatin improved chances of survival compared with S-1 alone ... The study, called Spirit, involved 305 patients who received either oral S-1 twice daily for 28 days, followed by a 14-day rest period, or oral S-1 twice daily for 21 days plus cisplatin on the eighth day of treatment, followed by the 14-day rest period ... "This study... (Scientific American)
The research looked at Avastin in combination with the chemotherapy drugs cisplatin and gemcitabine. That combination with Avastin is used less than one percent of the time in the U.S., said Genentech spokeswoman Kristina Becker. (Bloomberg)
In this single-arm, open-label study, 81 patients with Stage IIIB (18 percent) or Stage IV (82 percent) NSCLC were treated with OGX-011, 78 of whom were treated at the Phase II dose of 640 mg per week by intravenous infusion, in combination with a standard first-line NSCLC chemotherapy regimen that included gemcitabine and either cisplatin or carboplatin ... The most common grade 3 or 4 hematologic toxicities were neutropenia (47 percent in combination with cisplatin and 60 percent in... (Canada Newswire)
Patients received Erbitux once a week plus six cycles of the common chemotherapy drugs cisplatin or carboplatin and 5-fluorouracil every three weeks. Those in the control group received the chemotherapy without Erbitux. (Scientific American)
One study found, for the first time, that giving Avastin (bevacizumab) to patients with advanced non-small cell lung cancer, along with the chemotherapy drugs cisplatin and gemcitabine, slowed the growth of the cancer by up to 25 percent ... The new study looked at Avastin with chemotherapy drugs cisplatin and gemcitabine ... In a third study, adding the targeted therapy Erbitux (cetuximab) to a first-line chemotherapy that included cisplatin or carboplatin extended survival for patients with... (Forbes)
Lilly also has studied ALIMTA plus cisplatin for the first-line treatment of NSCLC. In the first quarter of 2007, a study of ALIMTA plus cisplatin versus GEMZAR plus cisplatin met its primary endpoint of non-inferiority relative to overall survival ... ALIMTA in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery ... The most common adverse events (grades... (EurekAlert!)
ALIMTA in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery ... The most common adverse events (grades 3/4) with ALIMTA in combination with cisplatin for the treatment of patients with MPM were neutropenia (24%); leukopenia (16%); anemia (6%); thrombocytopenia (5%); infection without neutropenia (2%); fatigue (17%); thrombsis/embolism 6%); nausea (12%);... (EurekAlert!)
A pump was supposed to deliver fluorouracil, a drug used to treat tumours, over four days, but it was given to Melanson over four hours, along with another chemotherapy drug, cisplatin ... " Investigators concluded that three main factors led to Melanson's death: Overdose of prescribed fluorouracil. Poor design of the chemotherapy protocol. Inability to mitigate from the lethal dose of fluorouracil with cisplatin. Written instructions given to the nurses about how to administer the drug were... (CBC.ca)
In one study, investigators examined the tumor-killing ability of reovirus plus cisplatin, a standard chemotherapy agent, in a mouse melanoma model that included both cultured cells and live animals. The results of the preclinical study showed that the combination of reovirus and cisplatin was significantly more effective than cisplatin or reovirus alone at killing melanoma cancer cells in a mouse model. (Science Daily)
She was given an electronic pump containing a four day dose of two chemotherapy drugs, 5-fluorouracil and cisplatin, to administer to herself at home. But unfortunately the pump was programmed to dispense the dose in four hours and not four days. (Medical News Today)
According to the report, on July 31 a nurse made the initial error after she misunderstood a pharmacist's prescription and then misprogrammed the electronic pump to disperse fluorouracil, a drug used to treat tumours, over four hours instead of the prescribed four days, along with another chemotherapy drug, cisplatin. A second nurse double-checked her work, but couldn't find a calculator and ended up doing the mathematical equation mentally and on a piece of paper. (Globe and Mail -- National)
In addition to rosizitaglone, the scientists tested pioglitazone and an experimental compound made by Glaxo Smith Kline, combining each of them with cisplatin, carboplatin and oxalyplatin -- all commonly used chemotherapy drugs that destroy cancer cells by damaging their DNA.. When non small-cell lung cancer cell lines were treated with rosizitaglone alone, there was no effect on growth. (Science Daily)
Researchers at the Massachusetts General Hospital (MGH) Cancer Center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors. They also have discovered the molecular basis of this sensitivity, which may help identify patients most likely to benefit from cisplatin treatment ... Triple-negative tumors are the most common subtype found in patients with mutations in the BRCA1 gene, but they also appear in... (Science Daily)
All patients on the trial had been treated with front line cisplatin combination chemotherapy, which failed to halt their disease. The clinical trial continues. (Science Daily)
The most common adverse events (grades 3/4) with ALIMTA in combination with cisplatin for the treatment of patients with MPM were neutropenia (24%); leukopenia (16%); anemia (6%); thrombocytopenia (5%); infection without neutropenia (2%); fatigue (17%); thrombosis/embolism (6%); nausea (12%); vomiting (11%); dyspnea (11%); and chest pain (9%) ... The most severe adverse events (grades 3/4) with GEMZAR plus cisplatin for the first-line treatment of patients with NSCLC were neutropenia (57%-64%);... (Canada Newswire)
The randomized, multi-center study, known as EXTREME, studied more than 400 patients treated with ERBITUX in combination either with cisplatin plus 5-fluorouracil (5-FU) or carboplatin plus 5-FU, compared to patients treated with cisplatin plus 5-FU or carboplatin plus 5-FU alone. "We are excited by the results of this study, as it is the first large, randomized clinical trial to examine the impact of ERBITUX treatment in combination with platinum-based chemotherapy on overall survival in... (PR Newswire)
But one area upon which there is agreement among medics is the need for the 'gold-standard' drug combination - Pemetrexed and Cisplatin - to be a routine part of the chemotherapy treatment of mesothelioma within the NHS. ... This leaves NHS mesothelioma patients no option but to undergo chemotherapy using the combination of Gemcitabine and Cisplatin ... I had the Gemcitabine and Cisplatin treatment, I didn't know there was an alernative. (Daily Mail)
Furthermore, the proteins of this pathway are largely responsible for the resistance of tumours to many antitumour agents such as cisplatin and other chemotherapeutic agents that kill tumour cells by producing DNA interstrand crosslinks. That is, they identify cellular alterations induced by chemotherapy and correct them, "accidentally" helping the tumour. (Science Daily)
In one study, Cerenia was tested on dogs with cancer undergoing chemotherapy with the drug cisplatin, which induces severe vomiting. In these trials, the drug was 95 percent effective in preventing vomiting on cisplatin, according to the drug agency. (Xinhuanet, China)
Feb. 22 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE: ) announced today that a Roche-sponsored Phase III study evaluating two different doses of Avastin(R) (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy met the primary endpoint of prolonging progression-free survival (PFS) in patients with previously untreated, advanced non-squamous, non-small cell lung cancer (NSCLC), the most common form of the disease. Both doses of Avastin (15 mg/kg or 7. (PR Newswire)
In 2006, Taxotere(R) was approved in the United States and Europe for two new indications: -- advanced stage gastric cancer in combination with the standard treatment (cisplatin and 5-fluorouracil) -- as induction treatment for patients with head and neck cancer in combination with a classic regimen (cisplatin and 5-fluorouracil). The FDA has granted a pediatric extension for Eloxatin(R) in the United States, extending the data protection period by six months until February 2007, as well as the... (PR Newswire)
In the study, patients receiving pemetrexed and cisplatin -- along with the vitamin supplements folic acid and B12 -- survived nearly three months longer than patients getting cisplatin alone ... "Pemetrexed used in combination with cisplatin significantly increases the length of survival, when compared with cisplatin alone," the researchers say ... Green J, et al. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant... (Science Daily)
More recently, chemotherapeutic regimes including Cisplatin, Vincristine and CCNU have been investigated and show promise in pediatric populations. These allow a reduction in the required radiation dose, but do not entirely prevent the above sequelae. (Suite101.com)
In their experiments, the researchers used a yolk consisting of iron and platinum, the metal responsible for the activity of the widely used chemotherapeutic drug, cisplatin. Cultures of human cancer cells took up the nanostructures and the nanostructures released their yolks, which proved to have "exceptionally high toxicity" for the cancer cells. (Science Daily)
(March 29, 2006) -- One of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. However, it also kills healthy tissue. (Science Daily)
A dose-intensive regimen of the chemotherapy drugs cisplatin and doxorubicin offered no clinical benefit over standard doses of the chemotherapy drugs in patients with a bone cancer called osteosarcoma, according to results from a randomized trial in the January 17 issue of the Journal of the National Cancer Institute ... A total of 497 patients age 40 or younger with high-grade osteosarcoma that had not spread elsewhere in the body were randomly assigned to receive six cisplatin--doxorubicin... (Science Daily)
FRIDAY, Jan. 19 (HealthDay News) -- Increasing the dose intensity of a chemotherapy regimen using the drugs cisplatin and doxorubicin did not produce better treatment results than using standard doses for patients with the bone cancer osteosarcoma, a new study finds ... One group received six cisplatin-doxorubicin treatments at three-week intervals (standard treatment) and the other group of patients received the treatments at two-week intervals (dose-intense treatment). (Health-Finder)
Certain chemotherapeutic agents, such as cisplatin, specifically impair carnitine reabsorption by the kidney. Carnitine deficiency is found in about half of cancer patients, Cruciani said. (MEDLINEplus)
The cancer doctor moved to Stony Brook and began studying a combination of cisplatin and etoposide - an intracarotid chemo cocktail. Since 1988, almost 80 patients have gone through the treatment protocol, which includes three infusions delivered in a two-month period, on the heels of surgery and before radiation. (Newsday -- Health)
Back to Chemistry News
©1998-2009 SurfWax, Inc.
All rights reserved. Patents pending.
Copyright SurfWax, Inc. 2009 |